Cargando…

Shifting the Disease Management Paradigm From Glucose: What are the pros?

Detalles Bibliográficos
Autores principales:	Stirban, Alin, Tschoepe, Diethelm, Stratmann, Bernd
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Diabetes and Cardiovascular Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811442/ https://www.ncbi.nlm.nih.gov/pubmed/19875579 http://dx.doi.org/10.2337/dc09-S337

Ejemplares similares

Heart in Diabetes: Not Only a Macrovascular Disease
por: Stratmann, Bernd, et al.
Publicado: (2011)

Shifting the Disease Management Paradigm From Glucose: What are the cons?
por: Hanefeld, Markolf, et al.
Publicado: (2009)

Glucose Control and Cardiovascular Disease: Is it important? No
por: Conget, Ignacio, et al.
Publicado: (2009)

Current Application of Continuous Glucose Monitoring in the Treatment of Diabetes: Pros and cons
por: Hermanides, Jeroen, et al.
Publicado: (2011)

Impact of GLO1 Knock Down on GLUT4 Trafficking and Glucose Uptake in L6 Myoblasts
por: Engelbrecht, Britta, et al.
Publicado: (2013)

Benfotiamine Counteracts Smoking-Induced Vascular Dysfunction in Healthy Smokers
por: Stirban, Alin, et al.
Publicado: (2012)

Peripheral oscillometric arterial performance does not depict coronary status in patients with type 2 diabetes mellitus
por: Jaeger, Magdalene, et al.
Publicado: (2021)

Acute Macrovascular Dysfunction in Patients With Type 2 Diabetes Induced by Ingestion of Advanced Glycated β-Lactoglobulins
por: Stirban, Alin, et al.
Publicado: (2013)

Vascular Effects of Dietary Advanced Glycation End Products
por: Stirban, Alin, et al.
Publicado: (2015)

Chronic Hyperglycaemia Inhibits Tricarboxylic Acid Cycle in Rat Cardiomyoblasts Overexpressing Glucose Transporter Type 4
por: Stratmann, Bernd, et al.
Publicado: (2022)

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines
por: Gallwitz, Baptist
Publicado: (2009)

Editorial: Conduction system pacing: What’s missing for the paradigm shift?
por: Marcantoni, Lina, et al.
Publicado: (2023)

Hypertension and Diabetes: What are the pros to treating early surrogates?
por: Schmieder, Roland E.
Publicado: (2009)

Treatment of Prehypertension in Diabetes and Metabolic Syndrome: What are the pros?
por: Segura, Julian, et al.
Publicado: (2009)

The Pros and Cons of Diagnosing Diabetes With A1C
por: Bonora, Enzo, et al.
Publicado: (2011)

Physical Activity, Sedentary Behavior, and Health: Paradigm Paralysis or Paradigm Shift?
por: Katzmarzyk, Peter T.
Publicado: (2010)

Liraglutide and DPP-4 inhibitors – side effects comparative clinical study
por: TIMOFTE, LUMINIŢA, et al.
Publicado: (2013)

Intracellular Accumulation of Methylglyoxal by Glyoxalase 1 Knock Down Alters Collagen Homoeostasis in L6 Myoblasts
por: Stratmann, Bernd, et al.
Publicado: (2017)

Heart in Diabetes: A Microvascular Disease
por: Laakso, Markku
Publicado: (2011)

Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease
por: Versari, Daniele, et al.
Publicado: (2009)

Getting to the “Heart” of the Matter on Diabetic Cardiovascular Disease: “Thanks for the Memory”
por: Cefalu, William T., et al.
Publicado: (2016)

Early Insulin Treatment in Type 2 Diabetes: What are the pros?
por: Meneghini, Luigi F.
Publicado: (2009)

Is Hyperglycemia a Causal Factor in Cardiovascular Disease?: Does proving this relationship really matter? Yes
por: Davidson, Jaime A., et al.
Publicado: (2009)

The Munich Myocardial Infarction Registry: Translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice
por: Schnell, Oliver, et al.
Publicado: (2009)

Viral Trigger for Type 1 Diabetes: Pros and Cons
por: Filippi, Christophe M., et al.
Publicado: (2008)

Association and pathways between shift work and cardiovascular disease: a prospective cohort study of 238 661 participants from UK Biobank
por: Ho, Frederick K, et al.
Publicado: (2021)

Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease
por: Aday, Aaron W., et al.
Publicado: (2019)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
por: Bianchi, Cristina, et al.
Publicado: (2009)

A Summary of the ADVANCE Trial
por: Heller, Simon R.
Publicado: (2009)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
por: Kassem, Sameer A., et al.
Publicado: (2009)

Postprandial Hyperglycemia and Glycemic Variability: Should we care?
por: Standl, Eberhard, et al.
Publicado: (2011)

Is Hyperglycemia a Cardiovascular Risk Factor?
por: Pistrosch, Frank, et al.
Publicado: (2011)

Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011)

Antiplatelet Therapy for Every Diabetic Person?
por: Nicolucci, Antonio, et al.
Publicado: (2011)

Should C-Reactive Protein Be a Target of Therapy?
por: Oh, Jisun, et al.
Publicado: (2011)

Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
por: Gori, Mauro, et al.
Publicado: (2016)

Limitations to functioning and independent living after the onset of coronary heart disease: what is the role of lifestyle factors and obesity?
por: Britton, Annie, et al.
Publicado: (2012)

Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
por: Li, Jiahua, et al.
Publicado: (2019)

Perspectives on Chronic Kidney Disease With Type 2 Diabetes and Risk Management: Practical Viewpoints and a Paradigm Shift Using a Pillar Approach
por: Morales, Javier, et al.
Publicado: (2023)

Metabolomic Signature of Coronary Artery Disease in Type 2 Diabetes Mellitus
por: Stratmann, Bernd, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_81l4rvgg2on8jpdj9sfdpdtdn0